Moderna, Health Canada and COVID-19
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
Why Australia could miss out on Moderna's new COVID-19 vaccine
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the government seemingly only intends to make one available to the public.
Moderna's updated COVID-19 vaccine approved in Canada
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax formula targets the KP.2 subvariant, one of the latest offshoots of the Omicron variant of the virus that causes COVID-19.
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
Moderna Gets Canada Approval for Updated Covid-19 Vaccine
Moderna said that the Canadian government has approved its updated Covid-19 Spikevax for individuals aged six months and older. The biotechnology company on Tuesday said that Health Canada authorized the vaccine targeting the KP.2 Covid-19 variant of Sars-Cov-2.
CNET on MSN2h
What to Know About Novavax, the 'Other' COVID Vaccine
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Be warned: Check your insurance before getting a COVID-19 vaccine this year
For those who are uninsured or under-insured, CDPH will have vaccine at its three CDPH Immunization Clinics. Walk-ins are ...
Palo Alto Weekly14h
Santa Clara County rolls out Covid shots after federal funding for vaccine ends
As winter approaches, Santa Clara County is rolling out an updated Covid-19 vaccine, but for some people, there is a hurdle ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
COVID Variants are Surging. Is It Time to Break Out the Face Masks Again?
The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...